Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases

Abstract

Prostate cancer (PCa) is one of the most common types of malignancy, most patients with PCa will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), which has a poor prognosis. Since 2004, chemotherapy has been approved by the FDA as the first-line treatment for mCRPC, and docetaxel-based regimens have been shown to improve both the patients’ symptoms and overall survival (OS). 10 cycles of docetaxel therapy are usually given to patients with mCPRC, but there is still no consensus on the optimal number of treatment cycles. Here, we present three cases of mCRPC patients that received maintenance long-term multiple-cycles docetaxel treatment. We believe that this new treatment strategy may benefit carefully selected mCRPC patients and provide several key advantages such as maximum exposure to drugs, improvements in drug efficacy, and reduce the risk of developing drug resistance.

Compliance with MDT recommendations is the key element for patients to benefit from MDT in complicated genitourinary tumors: a single-center data set

“…Complete response (CR) was observed after nine cycles of treatment and maintained after 41 months of follow-up (24). We also provided maintenance long-term multiple cycles of docetaxel chemotherapy for highly selected mCRPC patients, and a few patients seemed to bene t from this strategy (25). Thus, in our experience, MDT provided more opportunities for complex cases of genitourinary cancers, especially for patients who failed with standard treatments recommended by current guidelines.…”